Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-density lipoprotein subclasses and apolipoprotein A-I.

P Duriez1, J C Fruchart

  • 1Département d'Athérosclérose et INSERM U. 325, Institut Pasteur, Lille, France.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|October 8, 1999
PubMed
Summary

High-density lipoprotein (HDL) rich in apolipoprotein A-I (apo A-I) particles, known as LpA-I, protect against atherosclerosis. Other HDL particles containing both apo A-I and apo A-II (LpA-I:A-II) have a more controversial role in preventing heart disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis.

Metabolism: clinical and experimental·2001
Same author

Overview. PPAR and cardiovascular risk.

Journal of cardiovascular risk·2001
Same author

PPARS in inflammation, atherosclerosis and thrombosis.

Journal of cardiovascular risk·2001
Same author

[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].

Bulletin de l'Academie nationale de medecine·2001
Same author

Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans.

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity·2001
Same author

Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta.

The Journal of biological chemistry·2001

Area of Science:

  • Cardiovascular Science
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • Decreased high-density lipoprotein (HDL) cholesterol is linked to premature coronary artery disease.
  • HDL's protective mechanisms against atherosclerosis are under investigation.
  • HDL is classified into subpopulations based on apolipoprotein composition, notably LpA-I (apo A-I only) and LpA-I:A-II (apo A-I and apo A-II).

Purpose of the Study:

  • To investigate the differential roles of HDL subpopulations, specifically LpA-I and LpA-I:A-II, in preventing atherosclerosis.
  • To clarify the atheroprotective potential of apo A-I-rich versus apo A-I + apo A-II-rich HDL particles.

Main Methods:

  • Review of epidemiological and clinical studies on HDL and coronary artery disease.
  • Analysis of studies involving transgenic animals with gene transfer of human apo A-I and apo A-II.

Related Experiment Videos

  • Examination of cellular cholesterol efflux promotion by different HDL subpopulations.
  • Consideration of immunological methods for measuring LpA-I and LpA-I:A-II levels.

    • Main Results:

    • LpA-I is generally more effective than LpA-I:A-II in promoting cellular cholesterol efflux.
    • Gene transfer of apo A-I in animal models increases HDL cholesterol and inhibits atherosclerosis.
    • Gene transfer of apo A-II yields conflicting results regarding its role in atherosclerosis, suggesting it may be atherogenic or have a variable anti-atherogenic effect.
    • Clinical studies indicate LpA-I is a strong marker for atherosclerosis protection, while the significance of LpA-I:A-II is debated.

    Conclusions:

    • Apo A-I-rich HDL particles (LpA-I) demonstrate significant atheroprotective effects.
    • The role of HDL particles containing both apo A-I and apo A-II (LpA-I:A-II) in atherosclerosis prevention is less clear and requires further investigation.
    • Advancements in immunological methods enable large-scale studies to confirm the clinical significance of these distinct HDL subpopulations.